Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
HealthCentral CEO Justin Chase joins to discuss the drops app and its mission to combat medical misinformation and improve access to trusted health info.
Rob Thummel of Tortoise Capital breaks down oil prices, geopolitical risks, and what a volatile energy market could mean for investors and consumers this summer
Paul Dergarabedian, Head of Marketplace Trends for Comscore, joins to discuss Disney earnings, industry leadership shifts and the 2026 box office outlook today.
The new space race isn't about just astronauts, it's about data. Hawkeye 360 CEO John Serafini on satellites, national security, and the company's recent IPO.
